These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 22616398)

  • 41. Reducing the cost of rare disease drugs.
    Lancet; 2015 Feb; 385(9970):746. PubMed ID: 25752156
    [No Abstract]   [Full Text] [Related]  

  • 42. Rare disease resources not as rare as one might think.
    Burnworth MT
    Am J Health Syst Pharm; 2013 Jun; 70(12):1013-4. PubMed ID: 23719873
    [No Abstract]   [Full Text] [Related]  

  • 43. Why orphan drug coverage reimbursement decision-making needs patient and public involvement.
    Douglas CM; Wilcox E; Burgess M; Lynd LD
    Health Policy; 2015 May; 119(5):588-96. PubMed ID: 25641123
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Conference 1. An economic observatory for orphan drugs: myth or reality?].
    Duguet C; Ferry A
    Med Sci (Paris); 2014 Apr; 30 Spe(1):21-3. PubMed ID: 24755173
    [No Abstract]   [Full Text] [Related]  

  • 45. Duel over discounts. Pharma, providers at odds over 'orphan drugs'.
    Daly R
    Mod Healthc; 2012 Jan; 42(4):30-1. PubMed ID: 22359763
    [No Abstract]   [Full Text] [Related]  

  • 46. Orphan drugs and the NHS: fairness in health care entails more than cost effectiveness.
    Sheehan M
    BMJ; 2005 Nov; 331(7525):1144-5. PubMed ID: 16282416
    [No Abstract]   [Full Text] [Related]  

  • 47. Management of rare diseases.
    Walshe JM
    QJM; 2006 Feb; 99(2):123-4. PubMed ID: 16428334
    [No Abstract]   [Full Text] [Related]  

  • 48. Medicines for rare (orphan) diseases: an enquiry and proposal for tax-incentives.
    John JE
    Drug Discov Today; 2011 Dec; 16(23-24):999-1000. PubMed ID: 22020052
    [No Abstract]   [Full Text] [Related]  

  • 49. [Health care cantonal compensation fund project].
    Imsand C
    Rev Med Suisse; 2016 Mar; 12(509):527. PubMed ID: 27089648
    [No Abstract]   [Full Text] [Related]  

  • 50. Supplementing the fairness framework: system-level and implementation concerns.
    Majumder MA
    Am J Bioeth; 2004; 4(3):112-4; discussion W40-2. PubMed ID: 16192165
    [No Abstract]   [Full Text] [Related]  

  • 51. New drugs carry hefty price tags. Makers of leading-edge orphan products asked to cut prices, take smaller profits.
    Lee J
    Mod Healthc; 2013 Oct; 43(40):14. PubMed ID: 24340725
    [No Abstract]   [Full Text] [Related]  

  • 52. Orphan drugs: expensive yet necessary.
    Hyry HI; Roos JC; Cox TM
    QJM; 2015 Apr; 108(4):269-72. PubMed ID: 25434052
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Medicare and cost-effectiveness analysis.
    Neumann PJ; Rosen AB; Weinstein MC
    N Engl J Med; 2005 Oct; 353(14):1516-22. PubMed ID: 16207857
    [No Abstract]   [Full Text] [Related]  

  • 54. Are drugs for rare diseases "essential"?
    Reidenberg MM
    Bull World Health Organ; 2006 Sep; 84(9):686. PubMed ID: 17128329
    [No Abstract]   [Full Text] [Related]  

  • 55. Insuring kids in hard times: since it began, SCHIP has been taking care of children's medical needs. The question now, however, is how will it be funded.
    Oliver L
    State Legis; 2003 Mar; 29(3):32-4. PubMed ID: 15252943
    [No Abstract]   [Full Text] [Related]  

  • 56. Regulators adopt more orphan drugs.
    Reardon S
    Nature; 2014 Apr; 508(7494):16-7. PubMed ID: 24695293
    [No Abstract]   [Full Text] [Related]  

  • 57. Companies look for profit in orphan drugs.
    Thompson CA
    Am J Health Syst Pharm; 2010 Nov; 67(22):1892, 1895-6. PubMed ID: 21048203
    [No Abstract]   [Full Text] [Related]  

  • 58. Law and research could add up to profitable niche drugs.
    Haefner B
    Nature; 2007 Apr; 446(7138):856. PubMed ID: 17443162
    [No Abstract]   [Full Text] [Related]  

  • 59. Should oncologists support the Affordable Care Act?
    Kantarjian H; Steensma D; Light D
    Lancet Oncol; 2013 Dec; 14(13):1258-9. PubMed ID: 24275127
    [No Abstract]   [Full Text] [Related]  

  • 60. [Orphan drugs: drugs for rare diseases].
    Schenk M
    Dtsch Med Wochenschr; 2010 May; 135(18):p17. PubMed ID: 20455291
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.